Shipment term

Nemaura marks a historic milestone with the initial delivery of CGM aircraft

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investment advice.

Nemaura Medical NMRD is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible and affordable continuous glucose monitoring (CGM) device. “As part of its marketing strategy, NMRD recently made a first delivery of sugarBEAT devices to MySugarWatch Limited, its UK licensee. MySugarWatch Limited intends to market sugarBEAT via a subscription-based diabetes coaching and management service that targets over 4.9 million diabetics and 13.6 million people at increased risk of type 2 diabetes in UK,” reads a recent post that also features comments from Nemaura. CEO, Dr. Faz Chowdhury. “This initial delivery of sugarBEAT CGM devices to our UK licensee allows the company to recognize revenue for the first time in its history and is a real milestone in our development and growth,” said Dr Chowdhury. “Starting in the UK, patients with type 2 diabetes can now benefit from a less invasive blood glucose monitoring option that is expected to improve patient lifestyle, compliance and outcomes.”

To see the full article, visit

About Nemaura Medical Inc.

Nemaura is a medical technology company that develops and markets portable non-invasive diagnostic devices. The company currently markets sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE Mark-approved Class IIb medical device, is a non-invasive and flexible Continuous Glucose Monitor (“CGM”) providing actionable insights derived from real-time blood glucose measurements and daily glucose trending data. blood sugar, which can help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the US FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and was launched in the United States as a general wellness product as part of its BEAT diabetes program which is currently undergoing pilot studies. Additionally, Nemaura launched Miboko, a new program using a non-invasive glucose sensor as well as an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact their metabolic health and metabolic rate. well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being. The company sits at the intersection of the global type 2 diabetes market expected to grow to nearly $59 billion by 2025, the prediabetics market of over $50 billion, and the wearable health technology sector. for weight loss and wellness applications which is expected to reach $60 billion by 2023. For more information, please visit

NOTICE TO INVESTORS: The latest news and updates regarding NMRD can be found in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of corporate communications solutions. As a multi-faceted financial news and content distribution company with an extensive team of journalists and writers, BMW is uniquely positioned to better serve private and public companies seeking to reach large audiences in investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 major syndication outlets across the country. By reducing the information overload in today’s market, BMW provides customers with unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS alerts from BioMedWire, text “STOCKS” to 77948 (US cell phones only)

For more information, please visit

Please review the full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever posted or republished:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Image from Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investment advice.